Cargando…

Prognosis of metastatic renal cell carcinoma with first‐line interferon‐α therapy in the era of molecular‐targeted therapy

The RCC‐SELECT study showed the correlation between single nucleotide polymorphisms (SNP) in STAT3 gene and survival in metastatic renal cell carcinoma (mRCC) patients with first‐line interferon‐α (IFN‐α). In that study, even patients with STAT3 SNP linked to shorter overall survival (OS) exhibited...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawano, Yoshiaki, Takahashi, Wataru, Eto, Masatoshi, Kamba, Tomomi, Miyake, Hideaki, Fujisawa, Masato, Kamai, Takao, Uemura, Hirotsugu, Tsukamoto, Taiji, Azuma, Haruhito, Matsubara, Akio, Nishimura, Kazuo, Nakamura, Tsuyoshi, Ogawa, Osamu, Naito, Seiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946720/
https://www.ncbi.nlm.nih.gov/pubmed/27089226
http://dx.doi.org/10.1111/cas.12951
_version_ 1782443063256285184
author Kawano, Yoshiaki
Takahashi, Wataru
Eto, Masatoshi
Kamba, Tomomi
Miyake, Hideaki
Fujisawa, Masato
Kamai, Takao
Uemura, Hirotsugu
Tsukamoto, Taiji
Azuma, Haruhito
Matsubara, Akio
Nishimura, Kazuo
Nakamura, Tsuyoshi
Ogawa, Osamu
Naito, Seiji
author_facet Kawano, Yoshiaki
Takahashi, Wataru
Eto, Masatoshi
Kamba, Tomomi
Miyake, Hideaki
Fujisawa, Masato
Kamai, Takao
Uemura, Hirotsugu
Tsukamoto, Taiji
Azuma, Haruhito
Matsubara, Akio
Nishimura, Kazuo
Nakamura, Tsuyoshi
Ogawa, Osamu
Naito, Seiji
author_sort Kawano, Yoshiaki
collection PubMed
description The RCC‐SELECT study showed the correlation between single nucleotide polymorphisms (SNP) in STAT3 gene and survival in metastatic renal cell carcinoma (mRCC) patients with first‐line interferon‐α (IFN‐α). In that study, even patients with STAT3 SNP linked to shorter overall survival (OS) exhibited remarkably improved prognosis. All 180 patients evaluated in the above study were further analyzed for correlation between OS and demographics/clinicopathological parameters. OS was estimated using the Kaplan–Meier method. Associations between OS and potential prognostic factors were assessed using the log‐rank test and the Cox proportional hazards model. The median OS was 42.8 months. Univariate analysis showed that worse Eastern Cooperative Oncology Group‐performance status (ECOG‐PS), high T stage, regional lymph node metastasis, distant metastasis, higher grade, infiltrative growth pattern, the presence of microscopic vascular invasion (MVI), hypercalcemia, anemia, thrombocytopenia and elevated C‐reactive protein were significantly associated with OS. Multivariate analysis revealed that ECOG‐PS (hazard ratio [HR] = 3.665, P = 0.0004), hypercalcemia (HR = 6.428, P = 0.0005) and the presence of MVI (HR = 2.668, P = 0.0109) were jointly significant poor prognostic factors. This is the first study analysing prognostic factors of mRCC patients with first‐line IFN‐α using large cohort of the prospective study. The present study suggests that first‐line IFN‐α is still a useful therapy for mRCC even in the era of molecular targeted therapy.
format Online
Article
Text
id pubmed-4946720
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-49467202016-07-27 Prognosis of metastatic renal cell carcinoma with first‐line interferon‐α therapy in the era of molecular‐targeted therapy Kawano, Yoshiaki Takahashi, Wataru Eto, Masatoshi Kamba, Tomomi Miyake, Hideaki Fujisawa, Masato Kamai, Takao Uemura, Hirotsugu Tsukamoto, Taiji Azuma, Haruhito Matsubara, Akio Nishimura, Kazuo Nakamura, Tsuyoshi Ogawa, Osamu Naito, Seiji Cancer Sci Original Articles The RCC‐SELECT study showed the correlation between single nucleotide polymorphisms (SNP) in STAT3 gene and survival in metastatic renal cell carcinoma (mRCC) patients with first‐line interferon‐α (IFN‐α). In that study, even patients with STAT3 SNP linked to shorter overall survival (OS) exhibited remarkably improved prognosis. All 180 patients evaluated in the above study were further analyzed for correlation between OS and demographics/clinicopathological parameters. OS was estimated using the Kaplan–Meier method. Associations between OS and potential prognostic factors were assessed using the log‐rank test and the Cox proportional hazards model. The median OS was 42.8 months. Univariate analysis showed that worse Eastern Cooperative Oncology Group‐performance status (ECOG‐PS), high T stage, regional lymph node metastasis, distant metastasis, higher grade, infiltrative growth pattern, the presence of microscopic vascular invasion (MVI), hypercalcemia, anemia, thrombocytopenia and elevated C‐reactive protein were significantly associated with OS. Multivariate analysis revealed that ECOG‐PS (hazard ratio [HR] = 3.665, P = 0.0004), hypercalcemia (HR = 6.428, P = 0.0005) and the presence of MVI (HR = 2.668, P = 0.0109) were jointly significant poor prognostic factors. This is the first study analysing prognostic factors of mRCC patients with first‐line IFN‐α using large cohort of the prospective study. The present study suggests that first‐line IFN‐α is still a useful therapy for mRCC even in the era of molecular targeted therapy. John Wiley and Sons Inc. 2016-06-14 2016-07 /pmc/articles/PMC4946720/ /pubmed/27089226 http://dx.doi.org/10.1111/cas.12951 Text en © 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Kawano, Yoshiaki
Takahashi, Wataru
Eto, Masatoshi
Kamba, Tomomi
Miyake, Hideaki
Fujisawa, Masato
Kamai, Takao
Uemura, Hirotsugu
Tsukamoto, Taiji
Azuma, Haruhito
Matsubara, Akio
Nishimura, Kazuo
Nakamura, Tsuyoshi
Ogawa, Osamu
Naito, Seiji
Prognosis of metastatic renal cell carcinoma with first‐line interferon‐α therapy in the era of molecular‐targeted therapy
title Prognosis of metastatic renal cell carcinoma with first‐line interferon‐α therapy in the era of molecular‐targeted therapy
title_full Prognosis of metastatic renal cell carcinoma with first‐line interferon‐α therapy in the era of molecular‐targeted therapy
title_fullStr Prognosis of metastatic renal cell carcinoma with first‐line interferon‐α therapy in the era of molecular‐targeted therapy
title_full_unstemmed Prognosis of metastatic renal cell carcinoma with first‐line interferon‐α therapy in the era of molecular‐targeted therapy
title_short Prognosis of metastatic renal cell carcinoma with first‐line interferon‐α therapy in the era of molecular‐targeted therapy
title_sort prognosis of metastatic renal cell carcinoma with first‐line interferon‐α therapy in the era of molecular‐targeted therapy
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946720/
https://www.ncbi.nlm.nih.gov/pubmed/27089226
http://dx.doi.org/10.1111/cas.12951
work_keys_str_mv AT kawanoyoshiaki prognosisofmetastaticrenalcellcarcinomawithfirstlineinterferonatherapyintheeraofmoleculartargetedtherapy
AT takahashiwataru prognosisofmetastaticrenalcellcarcinomawithfirstlineinterferonatherapyintheeraofmoleculartargetedtherapy
AT etomasatoshi prognosisofmetastaticrenalcellcarcinomawithfirstlineinterferonatherapyintheeraofmoleculartargetedtherapy
AT kambatomomi prognosisofmetastaticrenalcellcarcinomawithfirstlineinterferonatherapyintheeraofmoleculartargetedtherapy
AT miyakehideaki prognosisofmetastaticrenalcellcarcinomawithfirstlineinterferonatherapyintheeraofmoleculartargetedtherapy
AT fujisawamasato prognosisofmetastaticrenalcellcarcinomawithfirstlineinterferonatherapyintheeraofmoleculartargetedtherapy
AT kamaitakao prognosisofmetastaticrenalcellcarcinomawithfirstlineinterferonatherapyintheeraofmoleculartargetedtherapy
AT uemurahirotsugu prognosisofmetastaticrenalcellcarcinomawithfirstlineinterferonatherapyintheeraofmoleculartargetedtherapy
AT tsukamototaiji prognosisofmetastaticrenalcellcarcinomawithfirstlineinterferonatherapyintheeraofmoleculartargetedtherapy
AT azumaharuhito prognosisofmetastaticrenalcellcarcinomawithfirstlineinterferonatherapyintheeraofmoleculartargetedtherapy
AT matsubaraakio prognosisofmetastaticrenalcellcarcinomawithfirstlineinterferonatherapyintheeraofmoleculartargetedtherapy
AT nishimurakazuo prognosisofmetastaticrenalcellcarcinomawithfirstlineinterferonatherapyintheeraofmoleculartargetedtherapy
AT nakamuratsuyoshi prognosisofmetastaticrenalcellcarcinomawithfirstlineinterferonatherapyintheeraofmoleculartargetedtherapy
AT ogawaosamu prognosisofmetastaticrenalcellcarcinomawithfirstlineinterferonatherapyintheeraofmoleculartargetedtherapy
AT naitoseiji prognosisofmetastaticrenalcellcarcinomawithfirstlineinterferonatherapyintheeraofmoleculartargetedtherapy